Finance

Lists
LEGN:NASDAQ
Legend Biotech Corp
18,44 $
-0,19%
(-0,035) 1D
19 қаз., 14:43:17 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LEGN...
Open
18,55 $
High
18,92 $
Low
18,00 $
Mkt. cap
3,59 млрд
Avg. vol.
2,28 млн
Volume
1,14 млн
52-wk high
37,50 $
52-wk low
16,24 $
EPS
-0,50 $
Beta
0,57
Shares outstanding
194,49 млн
No. of employees
3 мың
Open
18,55 $
High
18,92 $
Low
18,00 $
Mkt. cap
3,59 млрд
Avg. vol.
2,28 млн
Volume
1,14 млн
52-wk high
37,50 $
52-wk low
16,24 $
EPS
-0,50 $
Beta
0,57
Shares outstanding
194,49 млн
No. of employees
3 мың
News stories
From web sources and news partners
About Legend Biotech Corp
CEO-
Employees3,2 мың
Founded2014 ж. 17 қар.
HeadquartersSomerset, Нью-Джерси, Америка Құрама Штаттары
Sector-
Analyst ratings
Based on 9 analysts giving stock ratings to LEGN in the past 3 months
Buy
Buy
5
Hold
4
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for LEGN in the last 3 months.
Highest
Current 18,44 $
68,00 $ (+268,66%)
Average
44,01 $ (+138,60%)
Lowest
24,00 $ (+30,12%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
65,00 $
+252,4%
10/19/2026
Ziyi Chen
Goldman Sachs
Buy
Maintained
38,09 $
+106,5%
10/14/2026
Etzer Darout
Barclays
Buy
Maintained
68,00 $
+268,7%
10/13/2026
Jessica Fye
J.P. Morgan
Hold
Maintained
33,00 $
+78,9%
10/09/2026
Leonid Timashev
RBC Capital
Buy
Maintained
56,00 $
+203,6%
10/08/2026
Ashwani Verma
UBS
Hold
Reiterated
24,00 $
+30,1%
10/02/2026
Terence Flynn
Morgan Stanley
Buy
Maintained
48,00 $
+160,2%
08/12/2026
Kostas Biliouris
Oppenheimer
Hold
Downgraded
40,00 $
+116,9%
08/12/2026
Yaron Werber
TD Cowen
Hold
Reiterated
24,00 $
+30,1%
08/12/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
64,00 $
+247%
06/15/2026
Asthika Goonewardene
Truist Financial
Buy
Maintained
70,00 $
+279,5%
03/13/2026
James Shin
Deutsche Bank
Buy
Reiterated
60,00 $
+225,3%
03/09/2026
Qize Ding
Rothschild & Co Redburn
Hold
Downgraded
24,00 $
+30,1%
02/12/2026
Last report
2026 ж. 11 там.
Fiscal period
Q2 2026
0,32 $ / 0,28 $
+14,29%beat
Revenue / Est. (USD)
387,50 млн / 351,75 млн
+10,16%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
272,33 млн
306,38 млн
305,10 млн
387,50 млн
Cost of goods sold
115,31 млн
123,46 млн
175,90 млн
137,40 млн
Cost of revenue
115,31 млн
123,46 млн
175,90 млн
137,40 млн
Research and development expenses
113,15 млн
101,33 млн
85,70 млн
96,00 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
87,33 млн
101,19 млн
90,10 млн
96,40 млн
Operating expense
200,48 млн
203,52 млн
179,00 млн
192,40 млн
Total operating expenses
315,78 млн
326,98 млн
354,90 млн
329,80 млн
Operating income
-43,45 млн
-20,60 млн
-49,80 млн
57,70 млн
Other non operating income
-654,00 м.
3,29 млн
-500,00 м.
-1,40 млн
EBT including unusual items
-39,07 млн
-19,60 млн
-53,10 млн
55,50 млн
EBT excluding unusual items
-39,07 млн
-20,57 млн
-53,10 млн
55,50 млн
Income tax expense
616,00 м.
11,22 млн
1,20 млн
22,30 млн
Effective tax rate
-1,58%
-57,23%
-2,26%
40,18%
Other operating expenses
-
1,00 млн
3,20 млн
-
Net income
-39,69 млн
-30,82 млн
-54,30 млн
33,20 млн
Net profit margin
-14,57%
-10,06%
-17,80%
8,57%
Earnings per share
-0,22
-0,16
-0,28
0,32
Interest and investment income
9,66 млн
7,95 млн
7,30 млн
5,60 млн
Interest expense
-4,50 млн
-7,80 млн
-4,20 млн
-3,90 млн
Net interest expenses
5,16 млн
150,00 м.
3,10 млн
1,70 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-41,53 млн
-17,92 млн
-47,40 млн
61,70 млн
Gain or loss from assets sale
-250,00 м.
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google қолданбалары